Rorγt agonist enhances anti-pd-1 therapy by promoting monocyte-derived dendritic cells through cxcl10 in cancers

HIGHLIGHTS

• who: Li Xia from the (UNIVERSITY) have published the research work: RORu03b3t agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers, in the Journal: (JOURNAL)
• what: In Fig 5a and c, the authors show that an increase in IL-17A content in the tumor tissues of LLC mice treated with 8-074 was observed compared with vehicle alone. The authors reported a novel synthetic RORu03b3t agonist named 8-074 that selectively targets RORu03b3t and can enhance the differentiation of both murine Type 17 T_cells and human Type 17 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.